Art. -Nr.: HY-120508

Pivanex

(Synonyms: AN-9; Pivalyloxymethyl butyrate)

Kundenbewertung

Based on 1 Customer Validation

Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 95.0%
CAS. Nr.: 122110-53-6
Formel: C₁₀H₁₈O₄
Molecular Weight:202.25

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Pivanex Chemical Structure

CAS. Nr.: 122110-53-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HDAC

Bcr-Abl

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen :

Abl
Bcr-Abl

Cellular Effect

Cell Line	Type	Value	Description	References
3LLD122	IC₅₀	35 μM Compound: AN9	Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50% Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%	[PMID: 10956204]
B16-F10	IC₅₀	60 μM Compound: 1a	Effect on appearance of B16F10.9 colonies in semisolid agar Effect on appearance of B16F10.9 colonies in semisolid agar	[PMID: 1542095]
B16-F10	IC₅₀	82 μM Compound: 1a	Inhibitory activity on growth of B16F10.9 melanoma cell line Inhibitory activity on growth of B16F10.9 melanoma cell line	[PMID: 1542095]
HL-60	IC₅₀	36 μM Compound: AN-9	Concentration required for 50% inhibition of human HL-60 cell proliferation Concentration required for 50% inhibition of human HL-60 cell proliferation	[PMID: 15715472]
HL-60	IC₅₀	49 μM Compound: AN-9	Concentration required for 50% inhibition of human HL-60 MX2 cell proliferation Concentration required for 50% inhibition of human HL-60 MX2 cell proliferation	[PMID: 15715472]
HL-60	IC₅₀	49.5 μM Compound: 1a	Concentration required for 50% proliferation inhibition of human promyelocytic HL-60 cell line Concentration required for 50% proliferation inhibition of human promyelocytic HL-60 cell line	[PMID: 1542095]
HT-29	IC₅₀	52 μM Compound: AN-9	Concentration required for 50% inhibition of human HT-29 cell proliferation Concentration required for 50% inhibition of human HT-29 cell proliferation	[PMID: 15715472]
MES-SA	IC₅₀	40 μM Compound: AN-9	Concentration required for 50% inhibition of human MES-SA cell proliferation Concentration required for 50% inhibition of human MES-SA cell proliferation	[PMID: 15715472]
MIA PaCa-2	IC₅₀	30 μM Compound: AN9	Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50% Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%	[PMID: 10956204]
PC-3	IC₅₀	56 μM Compound: AN-9	Concentration required for 50% inhibition of human PC-3 cell proliferation Concentration required for 50% inhibition of human PC-3 cell proliferation	[PMID: 15715472]
WEHI	IC₅₀	75 μM Compound: 1a	Concentration required for 50% proliferation inhibition of myelomonocytic WEHI cell line Concentration required for 50% proliferation inhibition of myelomonocytic WEHI cell line	[PMID: 1542095]

In Vitro

Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells^[1].
Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells^[1].
Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle^[1].
Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

K562 cells.
Concentration:

100-500 μM.
Incubation Time:

24 hours.
Result:

Reduced the number of K562 viable cells significantly.
100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically.

Apoptosis Analysis^[1]

Cell Line:

K562 cells.
Concentration:

100-500 μM.
Incubation Time:

6-72 hours.
Result:

Increased the number of K562 apoptotic cells significantly.
Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM.

In Vivo

Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SMN7 SMA mice (SMN2^+/+; SMN7^+/+; mSmn^−/−)^[3].
Dosage:

200 mg/kg.
Administration:

Oral administration, b.i.d, at 09.00 and 17.00 daily.
Result:

Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.
Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 122110-53-6
Appearance Liquid (Density: 1.008±0.06 g/cm³)
Molecular Weight 202.25
Formel C₁₀H₁₈O₄
Color Colorless to light yellow
SMILES

CCCC(OCOC(C(C)(C)C)=O)=O
Synonyms

AN-9; Pivalyloxymethyl butyrate
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (494.44 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.9444 mL

24.7219 mL

49.4438 mL

5 mM

0.9889 mL

4.9444 mL

9.8888 mL

10 mM

0.4944 mL

2.4722 mL

4.9444 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rabizadeh E, et al. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leuk Res. 2007 Aug;31(8):1115-23. Epub 2007 Jan 30. [Content Brief]

[2]. Batova A, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002 Nov 1;100(9):3319-24. [Content Brief]

[3]. Edwards JD, et al. Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy. J Neuromuscul Dis. 2016 Nov 29;3(4):511-515. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.9444 mL	24.7219 mL	49.4438 mL	123.6094 mL
	5 mM	0.9889 mL	4.9444 mL	9.8888 mL	24.7219 mL
	10 mM	0.4944 mL	2.4722 mL	4.9444 mL	12.3609 mL
	15 mM	0.3296 mL	1.6481 mL	3.2963 mL	8.2406 mL
	20 mM	0.2472 mL	1.2361 mL	2.4722 mL	6.1805 mL
	25 mM	0.1978 mL	0.9889 mL	1.9778 mL	4.9444 mL
	30 mM	0.1648 mL	0.8241 mL	1.6481 mL	4.1203 mL
	40 mM	0.1236 mL	0.6180 mL	1.2361 mL	3.0902 mL
	50 mM	0.0989 mL	0.4944 mL	0.9889 mL	2.4722 mL
	60 mM	0.0824 mL	0.4120 mL	0.8241 mL	2.0602 mL
	80 mM	0.0618 mL	0.3090 mL	0.6180 mL	1.5451 mL
	100 mM	0.0494 mL	0.2472 mL	0.4944 mL	1.2361 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Pivanex

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Pivanex Related Classifications

HY-120508 Related Classifications